The  ||| S:0 E:4 ||| DT
importance  ||| S:4 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
non-lipid  ||| S:18 E:28 ||| JJ
risk  ||| S:28 E:33 ||| NN
factors ||| S:33 E:40 ||| NNS
:  ||| S:40 E:42 ||| :
a  ||| S:42 E:44 ||| DT
review  ||| S:44 E:51 ||| NN
focusing  ||| S:51 E:60 ||| VBG
on  ||| S:60 E:63 ||| IN
C-reactive  ||| S:63 E:74 ||| JJ
protein  ||| S:74 E:82 ||| NN
Identification  ||| S:82 E:97 ||| NNS
of  ||| S:97 E:100 ||| IN
individuals  ||| S:100 E:112 ||| NNS
at  ||| S:112 E:115 ||| IN
risk  ||| S:115 E:120 ||| NN
before  ||| S:120 E:127 ||| IN
the  ||| S:127 E:131 ||| DT
development  ||| S:131 E:143 ||| NN
of  ||| S:143 E:146 ||| IN
atherosclerosis-related  ||| S:146 E:170 ||| JJ
diseases  ||| S:170 E:179 ||| NNS
is  ||| S:179 E:182 ||| VBZ
important  ||| S:182 E:192 ||| JJ
for  ||| S:192 E:196 ||| IN
preventive  ||| S:196 E:207 ||| JJ
cardiology ||| S:207 E:217 ||| NN
.  ||| S:217 E:219 ||| .
Current  ||| S:219 E:227 ||| JJ
risk  ||| S:227 E:232 ||| NN
calculators  ||| S:232 E:244 ||| NNS
are  ||| S:244 E:248 ||| VBP
not  ||| S:248 E:252 ||| RB
sufficient  ||| S:252 E:263 ||| JJ
to  ||| S:263 E:266 ||| TO
effectively  ||| S:266 E:278 ||| RB
discriminate  ||| S:278 E:291 ||| JJ
high-risk  ||| S:291 E:301 ||| JJ
individuals  ||| S:301 E:313 ||| NNS
from  ||| S:313 E:318 ||| IN
those  ||| S:318 E:324 ||| DT
having  ||| S:324 E:331 ||| VBG
a  ||| S:331 E:333 ||| DT
low  ||| S:333 E:337 ||| JJ
cardiovascular  ||| S:337 E:352 ||| JJ
risk ||| S:352 E:356 ||| NN
.  ||| S:356 E:358 ||| .
It  ||| S:358 E:361 ||| PRP
is  ||| S:361 E:364 ||| VBZ
obvious  ||| S:364 E:372 ||| JJ
that  ||| S:372 E:377 ||| IN
new  ||| S:377 E:381 ||| JJ
risk  ||| S:381 E:386 ||| NN
factors  ||| S:386 E:394 ||| NNS
are  ||| S:394 E:398 ||| VBP
needed  ||| S:398 E:405 ||| VBN
to  ||| S:405 E:408 ||| TO
be  ||| S:408 E:411 ||| VB
used  ||| S:411 E:416 ||| VBN
either  ||| S:416 E:423 ||| RB
alone  ||| S:423 E:429 ||| RB
or  ||| S:429 E:432 ||| CC
in  ||| S:432 E:435 ||| IN
conjunction  ||| S:435 E:447 ||| NN
with  ||| S:447 E:452 ||| IN
the  ||| S:452 E:456 ||| DT
current  ||| S:456 E:464 ||| JJ
risk  ||| S:464 E:469 ||| NN
calculators  ||| S:469 E:481 ||| NNS
to  ||| S:481 E:484 ||| TO
increase  ||| S:484 E:493 ||| VB
the  ||| S:493 E:497 ||| DT
accuracy  ||| S:497 E:506 ||| NN
of  ||| S:506 E:509 ||| IN
this  ||| S:509 E:514 ||| DT
discrimination ||| S:514 E:528 ||| NN
.  ||| S:528 E:530 ||| .
C-reactive  ||| S:530 E:541 ||| JJ
protein  ||| S:541 E:549 ||| NN
( ||| S:549 E:550 ||| -LRB-
CRP ||| S:550 E:553 ||| NNP
)  ||| S:553 E:555 ||| -RRB-
seems  ||| S:555 E:561 ||| VBZ
to  ||| S:561 E:564 ||| TO
be  ||| S:564 E:567 ||| VB
a  ||| S:567 E:569 ||| DT
good  ||| S:569 E:574 ||| JJ
candidate  ||| S:574 E:584 ||| NN
as  ||| S:584 E:587 ||| IN
a  ||| S:587 E:589 ||| DT
biomarker ||| S:589 E:598 ||| NN
,  ||| S:598 E:600 ||| ,
since  ||| S:600 E:606 ||| IN
it  ||| S:606 E:609 ||| PRP
has  ||| S:609 E:613 ||| VBZ
been  ||| S:613 E:618 ||| VBN
widely  ||| S:618 E:625 ||| RB
analyzed  ||| S:625 E:634 ||| VBN
in  ||| S:634 E:637 ||| IN
prospective  ||| S:637 E:649 ||| JJ
cohort  ||| S:649 E:656 ||| JJ
studies  ||| S:656 E:664 ||| NNS
and  ||| S:664 E:668 ||| CC
clinical  ||| S:668 E:677 ||| JJ
trials ||| S:677 E:683 ||| NNS
.  ||| S:683 E:685 ||| .
In  ||| S:685 E:688 ||| IN
this  ||| S:688 E:693 ||| DT
review ||| S:693 E:699 ||| NN
,  ||| S:699 E:701 ||| ,
the  ||| S:701 E:705 ||| DT
value  ||| S:705 E:711 ||| NN
of  ||| S:711 E:714 ||| IN
CRP  ||| S:714 E:718 ||| NNP
as  ||| S:718 E:721 ||| IN
a  ||| S:721 E:723 ||| DT
risk  ||| S:723 E:728 ||| NN
factor  ||| S:728 E:735 ||| NN
in  ||| S:735 E:738 ||| IN
atherosclerotic  ||| S:738 E:754 ||| JJ
heart  ||| S:754 E:760 ||| NN
disease  ||| S:760 E:768 ||| NN
is  ||| S:768 E:771 ||| VBZ
discussed ||| S:771 E:780 ||| VBN
.  ||| S:780 E:782 ||| .
